Pieris

Pieris Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing its Anticalin® class of biotherapeutics for the treatment of various currently incurable diseases. Their pipeline includes immuno-oncology multispecific products tailored to the tumor microenvironment, inhaled Anticalin® proteins for treating uncontrolled asthma, and half-life optimized Anticalin® proteins for treating anemia.